Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + mFOLFOX6
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
QL1706 + mFOLFOX6 is a combination therapy being investigated for the treatment of locally advanced rectal cancer (LARC), particularly in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) tumors. QL1706 (also known as PSB205) is a novel bifunctional MabPair product that co-expresses two engineered monoclonal antibodies targeting Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) in a fixed ratio from a single cell line. mFOLFOX6 is a standard chemotherapy regimen consisting of oxaliplatin, leucovorin, and 5-fluorouracil. In clinical trials led by Sun Yat-sen University, this combination is administered as part of a total neoadjuvant therapy (TNT) approach, often following short-course radiotherapy (SCRT). The strategy aims to leverage the synergistic effects of radiation and chemotherapy to prime the immune microenvironment, potentially overcoming the typical resistance of pMMR/MSS rectal cancers to single-agent immune checkpoint inhibition.
- Other names
- QL1706 plus mFOLFOX6QL-1706 plus mFOLFOX6QL 1706 plus mFOLFOX6
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on QL1706 + mFOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + mFOLFOX6.